サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1121687

神経膠腫（グリオーマ）治療の世界市場：業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

Glioma Treatment Market (Type: Low-grade and High-grade) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 163 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.91円
神経膠腫（グリオーマ）治療の世界市場：業界分析、規模、シェア、成長、動向、予測（2022年～2031年）
出版日: 2022年07月21日
発行: Transparency Market Research
ページ情報: 英文 163 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の神経膠腫（グリオーマ）治療市場について調査分析し、市場の促進要因や抑制要因、洞察、セグメント別の分析と予測、地域別分析、企業プロファイルなどを提供しています。

目次

第1章 序文

第2章 前提と調査手法

第3章 エグゼクティブサマリー：世界の神経膠腫（グリオーマ）治療市場

第4章 市場概要

  • イントロダクション
    • 定義
    • 業界の進化/発展
  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • 世界の神経膠腫（グリオーマ）治療市場の分析と予測（2017年～2031年）

第5章 主な洞察

  • 主要な業界イベント（合併と買収、製品発売、パートナーシップ）
  • パイプライン分析
  • 低悪性度神経膠腫（グリオーマ）：概要
  • 世界における有病率・発症率
  • 業界へのCOVID-19流行の影響

第6章 世界の神経膠腫（グリオーマ）治療市場の分析と予測：タイプ別

  • イントロダクションと定義
  • 主な調査結果/開発
  • 市場価値予測：タイプ別（2017年～2031年）
    • 低悪性度
    • 高悪性度
  • 市場の魅力：タイプ別

第7章 世界の神経膠腫（グリオーマ）治療市場の分析と予測：治療法別

  • イントロダクションと定義
  • 主な調査結果/開発
  • 市場価値予測：治療法別（2017年～2031年）
    • 手術
    • 放射線治療
    • 化学療法
    • 標的薬物療法
    • その他
  • 市場の魅力：治療法別

第8章 世界の神経膠腫（グリオーマ）治療市場の分析と予測：地域別

  • 主な調査結果
  • 市場価値予測：地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力：地域別

第9章 北米の神経膠腫（グリオーマ）治療市場の分析と予測

  • イントロダクション
    • 主な調査結果
  • 市場価値予測：タイプ別（2017年～2031年）
    • 低悪性度
    • 高悪性度
  • 市場価値予測：治療法別（2017年～2031年）
    • 手術
    • 放射線治療
    • 化学療法
    • 標的薬物療法
    • その他
  • 市場価値予測：国別（2017年～2031年）
    • 米国
    • カナダ
  • 市場魅力分析
    • タイプ別
    • 治療法別
    • 国別

第10章 欧州の神経膠腫（グリオーマ）治療市場の分析と予測

第11章 アジア太平洋地域の神経膠腫（グリオーマ）治療市場の分析と予測

第12章 ラテンアメリカの神経膠腫（グリオーマ）治療市場の分析と予測

第13章 中東・アフリカの神経膠腫（グリオーマ）治療市場の分析と予測

第14章 競合情勢

  • 市場参加者 - 競合マトリックス（階層・企業規模別）
  • 市場シェア分析：企業別（2021年）
  • 企業プロファイル
    • Bristol-Myers Squibb Company
    • Genentech, Inc. (F. Hoffmann-La Roche Ltd.)
    • Pfizer, Inc.
    • Merck & Co., Inc
    • Teva Pharmaceutical Industries Ltd
    • Sun Pharmaceutical Industries Ltd.
    • Amgen, Inc.
    • その他の有名企業
図表

List of Tables

  • Table 01: Global Glioma Treatment Market Value (US$ Mn) Forecasts, by Type, 2017-2031
  • Table 02: Global Glioma Treatment Market Value (US$ Mn) Forecast, by High-grade, 2017-2031
  • Table 03: Global Glioma Treatment Market Value (US$ Mn) Forecast, by Low-grade , 2017-2031
  • Table 04: Global Glioma Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2031
  • Table 05: Global Glioma Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 06: North America Glioma Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: North America Glioma Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 08: North America Glioma Treatment Market Value (US$ Mn) Forecast, by High-grade, 2017-2031
  • Table 09: North America Glioma Treatment Market Value (US$ Mn) Forecast, by Low-grade, 2017-2031
  • Table 10: North America Glioma Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2031
  • Table 11: Europe Glioma Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 12: Europe Glioma Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 13: Europe Glioma Treatment Market Value (US$ Mn) Forecast, by High-grade, 2017-2031
  • Table 14: Europe Glioma Treatment Market Value (US$ Mn) Forecast, by Low-grade, 2017-2031
  • Table 15: Europe Glioma Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2031
  • Table 16: Asia Pacific Glioma Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Asia Pacific Glioma Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 18: Asia Pacific Glioma Treatment Market Analysis and Value (US$ Mn) Forecast, by High-grade, 2017-2031
  • Table 19: Asia Pacific Glioma Treatment Market Value (US$ Mn) Forecast, by Low-grade, 2017-2031
  • Table 20: Asia Pacific Glioma Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2031
  • Table 21: Latin America Glioma Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Latin America Glioma Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 23: Latin America Glioma Treatment Market and Value (US$ Mn) Forecast, by High-grade, 2017-2031
  • Table 24: Latin-America Glioma Treatment Market Value (US$ Mn) Forecast, by Low-grade , 2017-2031
  • Table 25: Latin America Glioma Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2031
  • Table 26: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Country/Sub-region, 2017-2031
  • Table 27: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Type, 2017-2031
  • Table 28: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by High-grade, 2017-2031
  • Table 29: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Low-grade, 2017-2031
  • Table 30: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Treatment, 2017-2031

List of Figures

  • Figure 01: Global Glioma Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Glioma Treatment Market Value Share, by Type, 2021
  • Figure 03: Global Glioma Treatment Market Value Share, by Treatment, 2021
  • Figure 04: Global Glioma Treatment Market Value Share, by Region, 2021
  • Figure 05: 5-year Relative Survival Rate
  • Figure 06: Global Glioma Treatment Market, by Type, 2021 and 2031
  • Figure 07: Global Glioma Treatment Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 08: Global Glioma Treatment Market (US$ Mn), by High-grade, 2017-2031
  • Figure 09: Global Glioma Treatment Market (US$ Mn), by Low-grade , 2017-2031
  • Figure 10: Global Glioma Treatment Market, by Treatment, 2021 and 2031
  • Figure 11: Global Glioma Treatment Market Attractiveness Analysis, by Treatment, 2022-2031
  • Figure 12: Global Glioma Treatment Market (US$ Mn), by Surgery, 2017-2031
  • Figure 13: Global Glioma Treatment Market (US$ Mn), by Radiation Therapy , 2017-2031
  • Figure 14: Global Glioma Treatment Market (US$ Mn), by Chemotherapy, 2017-2031
  • Figure 15: Global Glioma Treatment Market (US$ Mn), by Targeted Drug therapy, 2017-2031
  • Figure 16: Global Glioma Treatment Market (US$ Mn), by Others, 2017-2031
  • Figure 17: Global Glioma Treatment Market, by Region, 2021 and 2031
  • Figure 18: Global Glioma Treatment Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 19: North America Glioma Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 20: North America Glioma Treatment Market, By Country, 2021 And 2031
  • Figure 21: North America Glioma Treatment Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 22: North America Glioma Treatment Market, by Type, 2021 and 2031
  • Figure 23: North America Glioma Treatment Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 24: North America Glioma Treatment Market, by Treatment, 2021 and 2031
  • Figure 25: North America Glioma Treatment Market Attractiveness Analysis, by Treatment, 2022-2031
  • Figure 26: Europe Glioma Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 27: Europe Glioma Treatment Market, by Country/Sub-region, 2021 and 2031
  • Figure 28: Europe Glioma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 29: Europe Glioma Treatment Market, by Type, 2021 and 2031
  • Figure 30: Europe Glioma Treatment Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 31: Europe Glioma Treatment Market, by Treatment, 2021 and 2031
  • Figure 32: Europe Glioma Treatment Market Attractiveness Analysis, by Treatment, 2022-2031
  • Figure 33: Asia Pacific Glioma Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 34: Asia Pacific Glioma Treatment Market, by Country/Sub-region, 2021 and 2031
  • Figure 35: Asia Pacific Glioma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 36: Asia Pacific Glioma Treatment Market, by Type, 2021 and 2031
  • Figure 37: Asia Pacific Glioma Treatment Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 38:Asia Pacific Glioma Treatment Market, by Treatment, 2021 and 2031
  • Figure 39: Asia Pacific Glioma Treatment Market Attractiveness Analysis, by Treatment, 2022-2031
  • Figure 40: Latin America Glioma Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 41: Latin America Treatment Market, by Country/Sub-region, 2021 and 2031
  • Figure 42: Latin America Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 43: Latin America Glioma Treatment Market, by Type, 2021 and 2031
  • Figure 44: Latin America Glioma Treatment Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 45: Latin America Glioma Treatment Market, by Treatment, 2021 and 2031
  • Figure 46: Latin America Glioma Treatment Market Attractiveness Analysis, by Treatment, 2022-2031
  • Figure 47: Middle East & Africa Glioma Treatment Market Analysis, Value (US$ Mn) Forecast, 2017-2031
  • Figure 48: Middle East & Africa Glioma Treatment Market Analysis and Forecast, 2021 and 2031
  • Figure 49: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Country/Sub-region, 2022-2031
  • Figure 50: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Type, 2021 and 2031
  • Figure 51: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Type, 2022-2031
  • Figure 52: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Treatment, 2021-2031
  • Figure 53: Middle East & Africa Glioma Treatment Market Analysis and Forecast, by Treatment, 2022-2031
  • Figure 54: Global Glioma Treatment Market Share Analysis/Ranking, by Company, 2021
目次
Product Code: TMRGL84872

The report provides revenue of the global glioma treatment market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global glioma treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the glioma treatment market.

The report delves into the competitive landscape of the global glioma treatment market. Key players operating in the global glioma treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global glioma treatment market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Glioma Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Glioma Treatment Market Analysis and Forecasts, 2017-2031

5. Key Insights

  • 5.1. Key Industry Events (Mergers & Acquisitions, Product Launches, Partnerships)
  • 5.2. Pipeline Analysis
  • 5.3. Low Grade Glioma: Overview
  • 5.4. Disease Prevalence Rate & Incidence Rate Globally
  • 5.5. Covid-19 Pandemic Impact on the Industry

6. Global Glioma Treatment Market Analysis and Forecast, by Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Type, 2017-2031
    • 6.3.1. Low-Grade
      • 6.3.1.1. grade I
      • 6.3.1.2. grade II
    • 6.3.2. High-grade
      • 6.3.2.1. grade III
      • 6.3.2.2. grade IV
  • 6.4. Market Attractiveness, by Type

7. Global Glioma Treatment Market Analysis and Forecast, by Treatment

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Treatment, 2017-2031
    • 7.3.1. Surgery
    • 7.3.2. Radiation Therapy
    • 7.3.3. Chemotherapy
    • 7.3.4. Targeted Drug Therapy
    • 7.3.5. Others
  • 7.4. Market Attractiveness, by Treatment

8. Global Glioma Treatment Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness, by Region

9. North America Glioma Treatment Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Type, 2017-2031
    • 9.2.1. Low-Grade
      • 9.2.1.1. grade I
      • 9.2.1.2. grade II
    • 9.2.2. High-grade
      • 9.2.2.1. grade III
      • 9.2.2.2. grade IV
  • 9.3. Market Value Forecast, by Treatment, 2017-2031
    • 9.3.1. Surgery
    • 9.3.2. Radiation Therapy
    • 9.3.3. Chemotherapy
    • 9.3.4. Targeted Drug Therapy
    • 9.3.5. Others
  • 9.4. Market Value Forecast, by Country, 2017-2031
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Type
    • 9.5.2. By Treatment
    • 9.5.3. By Country

10. Europe Glioma Treatment Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Type, 2017-2031
    • 10.2.1. Low-Grade
      • 10.2.1.1. grade I
      • 10.2.1.2. grade II
    • 10.2.2. High-grade
      • 10.2.2.1. grade III
      • 10.2.2.2. grade IV
  • 10.3. Market Value Forecast, by Treatment, 2017-2031
    • 10.3.1. Surgery
    • 10.3.2. Radiation Therapy
    • 10.3.3. Chemotherapy
    • 10.3.4. Targeted Drug Therapy
    • 10.3.5. Others
  • 10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Italy
    • 10.4.5. Spain
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Type
    • 10.5.2. By Treatment
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Glioma Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Type, 2017-2031
    • 11.2.1. Low-Grade
      • 11.2.1.1. grade I
      • 11.2.1.2. grade II
    • 11.2.2. High-grade
      • 11.2.2.1. grade III
      • 11.2.2.2. grade IV
  • 11.3. Market Value Forecast, by Treatment, 2017-2031
    • 11.3.1. Surgery
    • 11.3.2. Radiation Therapy
    • 11.3.3. Chemotherapy
    • 11.3.4. Targeted Drug Therapy
    • 11.3.5. Others
  • 11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Type
    • 11.5.2. By Treatment
    • 11.5.3. By Country/Sub-region

12. Latin America Glioma Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Type, 2017-2031
    • 12.2.1. Low-Grade
      • 12.2.1.1. grade I
      • 12.2.1.2. grade II
    • 12.2.2. High-grade
      • 12.2.2.1. grade III
      • 12.2.2.2. grade IV
  • 12.3. Market Value Forecast, by Treatment, 2017-2031
    • 12.3.1. Surgery
    • 12.3.2. Radiation Therapy
    • 12.3.3. Chemotherapy
    • 12.3.4. Targeted Drug Therapy
    • 12.3.5. Others
  • 12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Type
    • 12.5.2. By Treatment
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Glioma Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Type, 2017-2031
    • 13.2.1. Low-Grade
      • 13.2.1.1. grade I
      • 13.2.1.2. grade II
    • 13.2.2. High-grade
      • 13.2.2.1. grade III
      • 13.2.2.2. grade IV
  • 13.3. Market Value Forecast, by Treatment, 2017-2031
    • 13.3.1. Surgery
    • 13.3.2. Radiation Therapy
    • 13.3.3. Chemotherapy
    • 13.3.4. Targeted Drug Therapy
    • 13.3.5. Others
  • 13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Type
    • 13.5.2. By Treatment
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 14.2. Market Share Analysis By Company (2021)
  • 14.3. Company Profiles
    • 14.3.1. Bristol-Myers Squibb Company
      • 14.3.1.1. Company Overview
      • 14.3.1.2. Company Financials
      • 14.3.1.3. Growth Strategies
      • 14.3.1.4. SWOT Analysis
    • 14.3.2. Genentech, Inc. (F. Hoffmann-La Roche Ltd.
      • 14.3.2.1. Company Overview
      • 14.3.2.2. Company Financials
      • 14.3.2.3. Growth Strategies
      • 14.3.2.4. SWOT Analysis
    • 14.3.3. Pfizer, Inc.
      • 14.3.3.1. Company Overview
      • 14.3.3.2. Company Financials
      • 14.3.3.3. Growth Strategies
      • 14.3.3.4. SWOT Analysis
    • 14.3.4. Merck & Co., Inc
      • 14.3.4.1. Company Overview
      • 14.3.4.2. Company Financials
      • 14.3.4.3. Growth Strategies
      • 14.3.4.4. SWOT Analysis
    • 14.3.5. Teva Pharmaceutical Industries Ltd
      • 14.3.5.1. Company Overview
      • 14.3.5.2. Company Financials
      • 14.3.5.3. Growth Strategies
      • 14.3.5.4. SWOT Analysis
    • 14.3.6. Sun Pharmaceutical Industries Ltd.
      • 14.3.6.1. Company Overview
      • 14.3.6.2. Company Financials
      • 14.3.6.3. Growth Strategies
      • 14.3.6.4. SWOT Analysis
    • 14.3.7. Amgen, Inc.
      • 14.3.7.1. Company Overview
      • 14.3.7.2. Company Financials
      • 14.3.7.3. Growth Strategies
      • 14.3.7.4. SWOT Analysis
    • 14.3.8. Other prominent players
      • 14.3.8.1. Company Overview
      • 14.3.8.2. Company Financials
      • 14.3.8.3. Growth Strategies
      • 14.3.8.4. SWOT Analysis